Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Blood (2024) 143 (16): 1565–1575.

https://doi.org/10.1182/blood.2023022432

Published: 2024

Journal Articles

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew Lunning, Michael Wang, Jon Arnason, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison Sehgal, Scott R. Solomon, Nilanjan Ghosh, Christine Dehner, Yeonhee Kim, Ken Ogasawara, Ana Kostic, Tanya Siddiqi

Blood (2024) 143 (5): 404–416.

https://doi.org/10.1182/blood.2023020854

Published: 2024

Includes: Supplemental data

Journal Articles

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Jeremy S. Abramson, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Ken Ogasawara, Manali Kamdar

Blood (2023) 141 (14): 1675–1684.

https://doi.org/10.1182/blood.2022018730

Published: 2023

Includes: Supplemental data

Journal Articles

Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy

Blood (2021) 137 (13): 1832–1835.

https://doi.org/10.1182/blood.2020006245

Published: 2021

Includes: Supplemental data

Journal Articles

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Matthew Lunning, Julie Vose, Loretta Nastoupil, Nathan Fowler, Jan A. Burger, William G. Wierda, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Susan O’Brien

Blood (2019) 134 (21): 1811–1820.

https://doi.org/10.1182/blood.2019002118

Published: 2019

Includes: Supplemental data

Journal Articles

Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice

Blood (2017) 129 (19): 2645–2656.

https://doi.org/10.1182/blood-2016-08-733469

Published: 2017

Includes: Supplemental data

Journal Articles

Transcend NHL 001: Immunotherapy with the CD19-Directed CAR T-Cell Product JCAR017 Results in High Complete Response Rates in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Jeremy S. Abramson, MD, Lia Palomba, MD, Leo I Gordon, MD, Matthew Lunning, DO, Jon Arnason, MD, Andres Forero-Torres, MD, Tina M. Albertson, MD PhD, Victoria Shaw Exton, Claire Sutherland, PhD, Benhuai Xie, PhD, Susan Snodgrass, MD, Tanya Siddiqi, MD

Blood (2016) 128 (22): 4192.

https://doi.org/10.1182/blood.V128.22.4192.4192

Published: 2016

Journal Articles

A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas

Blood (2016) 128 (22): 2991.

https://doi.org/10.1182/blood.V128.22.2991.2991

Published: 2016

Journal Articles

Combination of Ublituximab, TGR-1202, and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma

Matthew Lunning, DO, Philip J Bierman, MD, R. Gregory Bociek, MD, Marshall T. Schreeder, MD, Susan Blumel, RN, BSN, Kathy Cutter, RN, BSN, Emily K. Pauli, BMBS, PharmD, Peter Sportelli, Hari P. Miskin, MS, Michael S. Weiss, Julie M Vose, MD

Blood (2016) 128 (22): 4197.

https://doi.org/10.1182/blood.V128.22.4197.4197

Published: 2016

Journal Articles

CREBBP Loss Cooperates with BCL2 Over-Expression to Promote Lymphoma in Mice

Blood (2016) 128 (22): 458.

https://doi.org/10.1182/blood.V128.22.458.458

Published: 2016

Journal Articles

DNA Copy Number Gains of TCF4 (E2-2) Are Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma

Blood (2016) 128 (22): 2686.

https://doi.org/10.1182/blood.V128.22.2686.2686

Published: 2016

Journal Articles

Safety and Efficacy of Enoxaparin Prophylaxis in Adults Receiving Peg-Asparaginase Containing Induction Regimens for Acute Lymphoblastic Leukemia (ALL)

Jayadev Manikkam Umakanthan, MBBS, Lori J. Maness, MD, Jiangtao Luo, Avyakta Kallam, MBBS, James O. Armitage, MD, Philip Bierman, MD, Julie M. Vose, MD, R. Gregory Bociek, MD, Matthew Lunning, DO, Krishna Gundabolu, MD, Vijaya R. Bhatt, MD

Blood (2016) 128 (22): 5154.

https://doi.org/10.1182/blood.V128.22.5154.5154

Published: 2016

Journal Articles

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Ajai Chari, MD, Saurabh Chhabra, MD, Saad Usmani, MD, Sarah Larson, MD, Ruben Niesvizky, MD, Jeffrey Matous, MD, Cristina Gasparetto, MD, Beata Holkova, MD, Matthew Lunning, DO, Jason Valent, MD, Larry D. Anderson, Jr., MD PhD, Chatchada Karanes, MD, Long Kwei, PhD, Lipo Chang, Thorsten Graef, MD PhD, Elizabeth Bilotti, MSN, Kevin McDonagh, MD

Blood (2015) 126 (23): 377.

https://doi.org/10.1182/blood.V126.23.377.377

Published: 2015

NARROW

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice

Transcend NHL 001: Immunotherapy with the CD19-Directed CAR T-Cell Product JCAR017 Results in High Complete Response Rates in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas

Combination of Ublituximab, TGR-1202, and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma

CREBBP Loss Cooperates with BCL2 Over-Expression to Promote Lymphoma in Mice

DNA Copy Number Gains of TCF4 (E2-2) Are Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma

Safety and Efficacy of Enoxaparin Prophylaxis in Adults Receiving Peg-Asparaginase Containing Induction Regimens for Acute Lymphoblastic Leukemia (ALL)

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only